+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anticoagulants Market - Global Forecast 2026-2032- Product Image
Anticoagulants Market - Global Forecast 2026-2032- Product Image
Sale

Anticoagulants Market - Global Forecast 2026-2032

  • Report

  • 195 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904671
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Anticoagulants Market is projected to reach USD 38.64 Billion in 2026. It is expected to continue growing at a CAGR of 5.53%, reaching USD 53.47 Billion by 2032.

The anticoagulants market is anchored by a large and growing clinical need: prevention and treatment of thromboembolic events in atrial fibrillation, venous thromboembolism, acute coronary syndromes, mechanical circulatory support, and perioperative care. Cardiovascular disease remains the world’s leading cause of death, and the Global Burden of Disease study estimated nearly 60 million people living with atrial fibrillation or flutter in 2019, creating sustained demand for safe, effective anticoagulation.

Market growth is being shaped by the shift from vitamin K antagonists and injectable heparins toward direct oral anticoagulants, supported by major cardiology guidelines that prefer DOACs over warfarin for many patients with nonvalvular atrial fibrillation. At the same time, warfarin, unfractionated heparin, and low-molecular-weight heparins remain essential in mechanical heart valves, severe renal impairment, pregnancy-specific scenarios, hospital protocols, and cost-sensitive health systems.

Transformative Shifts in the Anticoagulants Landscape

The anticoagulants landscape is transforming from laboratory-intensive, one-size-fits-all therapy toward individualized, digitally supported anticoagulation management. DOAC adoption has reduced routine monitoring burden for many patients, while reversal agents such as idarucizumab for dabigatran and andexanet alfa for factor Xa inhibitors have improved clinician confidence in managing severe bleeding events.

Strategic competition is intensifying around differentiated safety profiles, renal dosing, once-daily convenience, drug-drug interaction management, and real-world evidence. Health systems are also emphasizing integrated care pathways that connect cardiology, hematology, emergency medicine, pharmacy, and primary care to reduce preventable stroke, recurrent venous thromboembolism, and major bleeding.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical enabler across the anticoagulant value chain. In clinical settings, AI-enabled ECG screening, claims analysis, and electronic health record alerts can help identify undiagnosed atrial fibrillation, predict bleeding risk, and flag patients who may benefit from therapy review. These tools complement established scoring systems rather than replacing clinician judgment.

In research and commercialization, AI supports trial site selection, patient stratification, adverse event signal detection, and adherence analytics. The cumulative impact is a faster feedback loop between real-world outcomes and treatment optimization, especially where anticoagulant underuse, inappropriate dosing, renal function changes, and polypharmacy remain persistent sources of avoidable harm.

Key Regional Insights

Asia-Pacific is expanding rapidly as China, India, Japan, South Korea, and Australia confront aging populations, rising atrial fibrillation detection, and broader insurance coverage for chronic cardiovascular care. Japan and Australia show mature DOAC uptake supported by guideline alignment, while China and India combine large patient pools with ongoing access, affordability, and rural diagnostic-capacity challenges.

North America remains a high-value anticoagulants market due to strong DOAC penetration, advanced hospital systems, extensive specialty care, and robust post-marketing surveillance. Europe demonstrates guideline-driven prescribing, pharmacovigilance, and disciplined health technology assessment. Latin America is shaped by mixed public-private access, formulary decisions, and uneven specialist availability, while the Middle East is supported by healthcare modernization and high cardiometabolic disease burden. Africa continues to face heterogeneous access, with hospital-based thrombosis programs, anticoagulation clinics, essential medicine availability, and laboratory infrastructure influencing adoption patterns.

Key Group Insights

ASEAN demand is rising as cardiovascular risk factors increase and hospital networks improve diagnosis of atrial fibrillation and venous thromboembolism, though reimbursement variability keeps warfarin relevant. The GCC benefits from high healthcare investment, growing cardiometabolic disease burden, and rapid adoption of branded anticoagulant therapies in tertiary centers, supported by expanding specialty cardiology and emergency care capacity.

The European Union combines strong regulatory oversight, pharmacovigilance, and cost-effectiveness scrutiny, favoring therapies with clear real-world safety and value evidence. BRICS markets offer substantial volume opportunity because of population scale, expanding insurance coverage, and increasing diagnosis of atrial fibrillation and venous thromboembolism. G7 countries remain critical for premium launches, clinical evidence generation, guideline influence, and advanced real-world data infrastructure. NATO member countries add relevance through military and emergency medicine needs, including trauma care, perioperative anticoagulation protocols, air evacuation readiness, and standardized thromboprophylaxis practices across allied health systems.

Key Country Insights

The United States leads in anticoagulant spending, DOAC utilization, and real-world evidence generation, supported by advanced cardiology networks, electronic health record infrastructure, and broad access to reversal strategies. Canada emphasizes provincial reimbursement, structured chronic disease management, and evidence-based formulary decisions. Mexico and Brazil are growing through mixed public-private access, with Brazil’s large cardiovascular patient population and hospital-based care networks supporting long-term anticoagulant demand.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are shaped by national guidelines, tendering, cost-effectiveness reviews, and strong pharmacovigilance systems, whereas Russia maintains a larger role for established therapies alongside selective DOAC access. China and India are high-growth markets driven by patient volume, expanding diagnosis, and improving insurance coverage, although affordability and specialist distribution remain important constraints. Japan, Australia, and South Korea show strong specialist adoption, aging-driven demand, structured reimbursement, and increasing focus on renal dosing, polypharmacy, and bleeding-risk management.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence that proves both clinical benefit and health-system value, including lower stroke rates, reduced monitoring burden, fewer hospitalizations, safer transitions of care, and measurable adherence improvements. Real-world data should be segmented by renal function, age, comorbidity, concomitant antiplatelet therapy, frailty, and socioeconomic access to support payer and prescriber confidence.

Organizations should also invest in AI-enabled care pathways, clinician education, and patient support programs that reduce inappropriate dosing, therapy interruption, and discontinuation. Strategic partnerships with hospitals, pharmacies, digital health vendors, anticoagulation clinics, and emergency care networks can strengthen differentiation beyond molecule-level efficacy while improving outcomes in atrial fibrillation and venous thromboembolism care.

Research Methodology

The executive summary is grounded in secondary research from peer-reviewed medical literature, global disease burden studies, major cardiology and hematology guidelines, regulatory sources, and health-system evidence on anticoagulant utilization. The analysis considers approved therapy classes, clinical indications, regional access dynamics, reimbursement conditions, pharmacovigilance signals, and digital transformation trends.

Insights are synthesized using a market-oriented framework that evaluates demand drivers, treatment adoption, competitive differentiation, access conditions, and real-world outcomes. Emphasis is placed on verified clinical, regulatory, and epidemiological evidence rather than speculative market claims, market sizing, or forecast-based assumptions.

Conclusion

Anticoagulants remain indispensable to modern cardiovascular and thromboembolic care, with demand supported by aging populations, atrial fibrillation prevalence, venous thromboembolism burden, and expanding diagnostic capacity. DOACs continue to reshape treatment standards, but legacy therapies retain durable roles in specialized and cost-sensitive settings, including mechanical valves, severe renal impairment, pregnancy-related care, and selected inpatient protocols.

The next phase of market leadership will depend on safety differentiation, access expansion, real-world evidence, reversal strategies, and AI-supported care optimization. Organizations that combine clinical credibility with digital execution, payer-relevant outcomes, and patient-centered anticoagulation management will be best positioned for sustainable growth.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Anticoagulants Market, by Drug Class
7.1. Introduction
7.2. Direct Thrombin Inhibitors (DTIs)
7.2.1. Dabigatran
7.2.2. Argatroban
7.2.3. Bivalirudin
7.3. Heparin
7.4. Vitamin K Antagonists
8. Anticoagulants Market, by Route Of Administration
8.1. Introduction
8.2. Injectable
8.2.1. Intravenous
8.2.2. Subcutaneous
8.3. Oral
9. Anticoagulants Market, by End User
9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Clinics
9.4. Homecare Settings
9.5. Hospitals
10. Anticoagulants Market, by Distribution Channel
10.1. Introduction
10.2. Offline
10.3. Online Pharmacy
11. Anticoagulants Market, by Indication
11.1. Introduction
11.2. Atrial Fibrillation
11.3. Deep Vein Thrombosis
11.4. Pulmonary Embolism
11.5. Venous Thromboembolism Prevention
12. Anticoagulants Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. Anticoagulants Market, by Group
13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC
14. Anticoagulants Market, by Country
14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Laboratories
16.2. Amphastar Pharmaceuticals Inc.
16.3. Aspen Pharmacare Holdings Limited
16.4. Aurobindo Pharma Ltd.
16.5. Bayer AG
16.6. Boehringer Ingelheim International GmbH
16.7. Bristol-Myers Squibb Company
16.8. Daiichi Sankyo Company, Limited
16.9. Dr. Reddy’s Laboratories Ltd.
16.10. Eli Lilly and Company
16.11. Fresenius Kabi AG
16.12. Gland Pharma Ltd.
16.13. Hikma Pharmaceuticals plc
16.14. Johnson & Johnson Services Inc.
16.15. Laboratorios Farmacéuticos ROVI SA
16.16. Leo Pharma A/S
16.17. Merck & Co., Inc.
16.18. Novartis AG
16.19. Pfizer Inc.
16.20. Sanofi S.A.
16.21. STADA Arzneimittel AG
16.22. Teva Pharmaceutical Industries Limited
16.23. Viatris Inc.
16.24. Zydus Lifesciences Ltd.
List of Figures
FIGURE 1. GLOBAL ANTICOAGULANTS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ANTICOAGULANTS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ANTICOAGULANTS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ANTICOAGULANTS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ANTICOAGULANTS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTICOAGULANTS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ANTICOAGULANTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ANTICOAGULANTS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ANTICOAGULANTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ANTICOAGULANTS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ANTICOAGULANTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ANTICOAGULANTS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL ANTICOAGULANTS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL ANTICOAGULANTS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ANTICOAGULANTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL DIRECT THROMBIN INHIBITORS (DTIS) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL DIRECT THROMBIN INHIBITORS (DTIS) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL DIRECT THROMBIN INHIBITORS (DTIS) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL DABIGATRAN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL DABIGATRAN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL DABIGATRAN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL ARGATROBAN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL ARGATROBAN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL ARGATROBAN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL BIVALIRUDIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL BIVALIRUDIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL BIVALIRUDIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL HEPARIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL HEPARIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL HEPARIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL VITAMIN K ANTAGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL VITAMIN K ANTAGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL VITAMIN K ANTAGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ATRIAL FIBRILLATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ATRIAL FIBRILLATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ATRIAL FIBRILLATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL DEEP VEIN THROMBOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL DEEP VEIN THROMBOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL DEEP VEIN THROMBOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL PULMONARY EMBOLISM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL PULMONARY EMBOLISM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL PULMONARY EMBOLISM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL VENOUS THROMBOEMBOLISM PREVENTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL VENOUS THROMBOEMBOLISM PREVENTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL VENOUS THROMBOEMBOLISM PREVENTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL ANTICOAGULANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 71. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 72. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 73. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 74. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 75. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 76. ASIA-PACIFIC ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 77. EUROPE ANTICOAGULANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. EUROPE ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 79. EUROPE ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 80. EUROPE ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 81. EUROPE ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 82. EUROPE ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 83. EUROPE ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 84. EUROPE ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 85. NORTH AMERICA ANTICOAGULANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. NORTH AMERICA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 87. NORTH AMERICA ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 88. NORTH AMERICA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 89. NORTH AMERICA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 90. NORTH AMERICA ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 91. NORTH AMERICA ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 92. NORTH AMERICA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 93. LATIN AMERICA ANTICOAGULANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. LATIN AMERICA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 95. LATIN AMERICA ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 96. LATIN AMERICA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 97. LATIN AMERICA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 98. LATIN AMERICA ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 99. LATIN AMERICA ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 100. LATIN AMERICA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 101. AFRICA ANTICOAGULANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. AFRICA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 103. AFRICA ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 104. AFRICA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 105. AFRICA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 106. AFRICA ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 107. AFRICA ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 108. AFRICA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 109. MIDDLE EAST ANTICOAGULANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. MIDDLE EAST ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 111. MIDDLE EAST ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 112. MIDDLE EAST ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 113. MIDDLE EAST ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 114. MIDDLE EAST ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 115. MIDDLE EAST ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 116. MIDDLE EAST ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL ANTICOAGULANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. NATO ANTICOAGULANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 119. NATO ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 120. NATO ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 121. NATO ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 122. NATO ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 123. NATO ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 124. NATO ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 125. NATO ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 126. G7 ANTICOAGULANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 127. G7 ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 128. G7 ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 129. G7 ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 130. G7 ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 131. G7 ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 132. G7 ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 133. G7 ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 134. BRICS ANTICOAGULANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 135. BRICS ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 136. BRICS ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 137. BRICS ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 138. BRICS ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 139. BRICS ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 140. BRICS ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 141. BRICS ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 142. EUROPEAN UNION ANTICOAGULANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 143. EUROPEAN UNION ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 144. EUROPEAN UNION ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 145. EUROPEAN UNION ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 146. EUROPEAN UNION ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 147. EUROPEAN UNION ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 148. EUROPEAN UNION ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 149. EUROPEAN UNION ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 150. ASEAN ANTICOAGULANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 151. ASEAN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 152. ASEAN ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 153. ASEAN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 154. ASEAN ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 155. ASEAN ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 156. ASEAN ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 157. ASEAN ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 158. GCC ANTICOAGULANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 159. GCC ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 160. GCC ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 161. GCC ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 162. GCC ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 163. GCC ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 164. GCC ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 165. GCC ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 166. GLOBAL ANTICOAGULANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 167. CHINA ANTICOAGULANTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 168. CHINA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 169. CHINA ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 170. CHINA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 171. CHINA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 172. CHINA ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 173. CHINA ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 174. CHINA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 175. UNITED STATES ANTICOAGULANTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 176. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 177. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 178. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 179. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 180. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 181. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 182. UNITED STATES ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 183. JAPAN ANTICOAGULANTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 184. JAPAN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 185. JAPAN ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 186. JAPAN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 187. JAPAN ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 188. JAPAN ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 189. JAPAN ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 190. JAPAN ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 191. INDIA ANTICOAGULANTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 192. INDIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 193. INDIA ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 194. INDIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 195. INDIA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 196. INDIA ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 197. INDIA ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 198. INDIA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 199. GERMANY ANTICOAGULANTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 200. GERMANY ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 201. GERMANY ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 202. GERMANY ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 203. GERMANY ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 204. GERMANY ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 205. GERMANY ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 206. GERMANY ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 207. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 208. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 209. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 210. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 211. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 212. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 213. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 214. UNITED KINGDOM ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 215. AUSTRALIA ANTICOAGULANTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 216. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 217. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 218. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 219. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 220. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 221. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 222. AUSTRALIA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 223. FRANCE ANTICOAGULANTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 224. FRANCE ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 225. FRANCE ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 226. FRANCE ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 227. FRANCE ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 228. FRANCE ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 229. FRANCE ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 230. FRANCE ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 231. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 232. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 233. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 234. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 235. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 236. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 237. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 238. SOUTH KOREA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 239. ITALY ANTICOAGULANTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 240. ITALY ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 241. ITALY ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 242. ITALY ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 243. ITALY ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 244. ITALY ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 245. ITALY ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 246. ITALY ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 247. CANADA ANTICOAGULANTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 248. CANADA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 249. CANADA ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 250. CANADA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 251. CANADA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 252. CANADA ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 253. CANADA ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 254. CANADA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 255. RUSSIA ANTICOAGULANTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 256. RUSSIA ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 257. RUSSIA ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 258. RUSSIA ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 259. RUSSIA ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 260. RUSSIA ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 261. RUSSIA ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 262. RUSSIA ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 263. BRAZIL ANTICOAGULANTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 264. BRAZIL ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 265. BRAZIL ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 266. BRAZIL ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 267. BRAZIL ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 268. BRAZIL ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 269. BRAZIL ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 270. BRAZIL ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 271. MEXICO ANTICOAGULANTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 272. MEXICO ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 273. MEXICO ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 274. MEXICO ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 275. MEXICO ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 276. MEXICO ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 277. MEXICO ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 278. MEXICO ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 279. SPAIN ANTICOAGULANTS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 280. SPAIN ANTICOAGULANTS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 281. SPAIN ANTICOAGULANTS MARKET SIZE, BY DIRECT THROMBIN INHIBITORS (DTIS), 2017-2032 (USD MILLION)
TABLE 282. SPAIN ANTICOAGULANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 283. SPAIN ANTICOAGULANTS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 284. SPAIN ANTICOAGULANTS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 285. SPAIN ANTICOAGULANTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 286. SPAIN ANTICOAGULANTS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 287. GLOBAL ANTICOAGULANTS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 288. GLOBAL ANTICOAGULANTS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Abbott Laboratories
  • Amphastar Pharmaceuticals Inc.
  • Aspen Pharmacare Holdings Limited
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol‑Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • Gland Pharma Ltd.
  • Hikma Pharmaceuticals plc
  • Johnson & Johnson Services Inc.
  • Laboratorios Farmacéuticos ROVI SA
  • Leo Pharma A/S
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • STADA Arzneimittel AG
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.
  • Zydus Lifesciences Ltd.

Table Information

Report AttributeDetails
No. of Pages195
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 38.64 Billion
Forecasted Market Value ( USD ) by 2032 $ 53.47 Billion
Compound Annual Growth Rate5.5%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Anticoagulant Reversal Drugs Market - Global Forecast 2026-2032 - Product Image

Anticoagulant Reversal Drugs Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Anticoagulant Reversal Agent Market - Global Forecast 2026-2032 - Product Image

Anticoagulant Reversal Agent Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Anticoagulants Market Size, Share & Trends Analysis Report by Drug Category, Route of Administration, Application, Pulmonary Embolism), and Region with Growth Forecasts, 2026-2033 - Product Image

Anticoagulants Market Size, Share & Trends Analysis Report by Drug Category, Route of Administration, Application, Pulmonary Embolism), and Region with Growth Forecasts, 2026-2033

  • Report
  • 100 Pages
  • Global
From
Direct Oral Anticoagulants (DOACs) Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Direct Oral Anticoagulants (DOACs) Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 185 Pages
  • Global
From
Anticoagulants Market Report 2026 - Product Image

Anticoagulants Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Anticoagulant Market

The anticoagulant market within the context of cardiovascular drugs is a rapidly growing sector of the pharmaceutical industry. Anticoagulants are drugs used to prevent the formation of blood clots, which can lead to serious medical conditions such as stroke and heart attack. These drugs are used to reduce the risk of thrombosis, a condition in which a blood clot forms in a blood vessel, blocking the flow of blood. Anticoagulants are also used to treat existing blood clots, as well as to prevent the formation of new ones. The anticoagulant market is driven by the increasing prevalence of cardiovascular diseases, such as coronary artery disease, stroke, and peripheral artery disease. The rising demand for anticoagulants is also driven by the increasing aging population, as well as the increasing awareness of the importance of preventive healthcare. Some of the major companies in the anticoagulant market include Bayer AG, Bristol-Myers Squibb, Pfizer, Sanofi, and Johnson & Johnson. These companies are engaged in the development, manufacture, and marketing of anticoagulant drugs. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.